GSK Avandia/Insulin Use Based On 220-Patient Study Showing No Cardio Risk
Executive Summary
GlaxoSmithKline's long-awaited approval of Avandia in combination with insulin is based on a 220-patient study showing no cardiovascular safety signal in type 2 diabetes patients
You may also be interested in...
GSK Trial Registry Begins With Avandia; Includes 25 Unpublished Studies
GlaxoSmithKline's clinical trial registry for the diabetes drug Avandia includes five unpublished placebo-controlled trials
GSK Trial Registry Begins With Avandia; Includes 25 Unpublished Studies
GlaxoSmithKline's clinical trial registry for the diabetes drug Avandia includes five unpublished placebo-controlled trials
Avandia/Metformin Combo To Launch By End Of 2002, GSK Says
GlaxoSmithKline's Avandia/metformin combination diabetes product will be launched by the end of 2002, GSK Chief Operating Officer Bob Ingram told securities analysts